GlobeNewswire
-
Kraig Labs Takes Biggest Step Yet and Ships First Commercial Spider Silk Order, as Performance Brand Set to Put Breakthrough Fiber to the Test
29/09/2026 -
20/20 BioLabs to Host Investor Webinar on October 7, 2026 to Discuss FDA Advisory Committee Vote and New OneTest™ Franchise Model
29/09/2026 -
Dank Cannabis Highlights Free Delivery Across Alberta, With Same-Day Service Until Midnight
29/09/2026 -
Integra LifeSciences Announces 100th Patient Enrolled in AERA® Pediatric Registry
29/09/2026 -
Milestone Scientific Highlights Building a Scalable Growth Platform for CompuFlo® Medical Business
29/09/2026 -
GATC Health's Derisq Named One of The Scientist's 2026 Top Innovations
29/09/2026 -
Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting
29/09/2026 -
Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results
29/09/2026 -
Lite Strategy Reports Fiscal Year 2026 Financial Results
29/09/2026 -
Celularity Announces Naveen Jain to Join Board of Directors
29/09/2026 -
TOMI Environmental Solutions Targets Next Phase of Growth in the Scaling Robotaxi, Drone and Robotics Economy
29/09/2026 -
J-Star Holding Co., Ltd. Chairman and CEO Jonathan Chiang to Relocate to the United States to Lead Growth Initiatives
29/09/2026 -
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting
29/09/2026 -
Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron
29/09/2026 -
Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD
29/09/2026 -
Apyx Medical Announces New Clinical Study Demonstrating Renuvion®’s Impact on Skin Quality
29/09/2026 -
NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease
29/09/2026 -
DiFusion to Define Therapeutic Biomaterials Category at NASS 2026
29/09/2026 -
Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)
29/09/2026
Pages